LENZ THERAPEUTICS

Topline CLARITY Results

Phase 3 Clinical Trials

April 3rd 2024

NASDAQ: LENZ

Disclaimer and Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “ projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of LENZ Therapeutics, Inc. (“LENZ,” “we” or “us”) management as well as assumptions made by and information currently available to LENZ. Such statements reflect the current views of LENZ with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about LENZ. Such statements may include, without limitation, statements regarding the potential of LNZ100 to have best-in-class performance; the timing of a potential FDA submission for LNZ100; the timing, progress and results of our clinical trials for our product candidates including statements regarding the reporting of data from our current trials; the size of the market opportunity for our product candidates, including our estimates of the size of the affected population and potential adoption rate; the beneficial characteristics of our product candidates; our competitive positioning; the development and commercialization of our products; and statements regarding our future financial or business performance. The clinical trial data in this presentation are topline and may change as more data and analyses are available. They are also subject to audit and other verification procedures that could result in material changes in the final data. This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets, our position and the positions of our competitors within these markets. We obtained the industry, market and similar data set forth in this presentation from internal company surveys, publicly available information, industry publications and surveys, and third-party studies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. More details about these and other risks that may impact LENZ’s business are described under the heading “Risk Factors” in LENZ Therapeutics, Inc.’s final 424B3 proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) on February 13, 2024, and in subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. LENZ cautions you not to place undue reliance on any forward-looking statement, which speak only as of the date hereof. LENZ does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.

LNZ100: potential best-in-class performance and selected as commercial candidate for mid-2024 NDA submission

Exclusive **aceclidine-only eye drop** with potential for providing seamless vision for the **full workday** for the **vast majority** of **128M US** presbyopes

- **Rapid onset** and **10-hour duration** 71%, 71% and 40% of participants achieved a ≥3-line improvement at 0.5, 3 and 10 hrs
- **Near universal response** with 95% and 69% of participants achieved at least a 2-line improvement at 1 and 10 hrs
- **Broadest population** tested in 45 - 75 y.o. presbyopes, inclusive of post-LASIK and pseudophakes[1]
- **Consistent high response** in near vision improvement over the 4-week efficacy study period[1]
- **Well tolerated** 95% of AEs mild[1] and 30,000+ LNZ100 treatment days without treatment related serious AE[2]
- **LNZ100 selected as commercial candidate** as LNZ101 showed similar but not superior performance

All data refers to LNZ100 CLARITY 2 – Vehicle Controlled, day 1 results unless otherwise specified; 1. Across CLARITY 1 & 2 Efficacy Trials; 2. Across all CLARITY Trials

CLARITY 1 and 2 Study Design

Randomized, double masked, controlled, Phase 3 trials (NCT05656027 & NCT05728944)

Ages 45 – 75, Mean 55 years	Refractive range -4D SE to +1D SE	Inclusive of post-LASIK presbyopes and pseudophakes	Baseline near visual acuity 20/50 or worse



	CLARITY 1 (n=469)	CLARITY 2 (n=229)	TOTAL (n=698)
LNZ100 (1.75% aceclidine)	157	77	234
LNZ101 (1.75% aceclidine & 0.08% brimonidine)	156	76	232
Control (CLARITY 1 = 0.08% brimonidine, CLARITY 2 = vehicle)	156	76	232

25 sites participated in CLARITY 1, and 17 sites participated in CLARITY 2

LNZ100 achieved rapid onset and 10 hours duration



Rapid onset with **71% of participants** achieving **≥3-Line improvement at 30 min**

Achieved **Primary Endpoint with 71%** participants achieving ≥3-Line improvement **at 3 hr**

Long Duration with **40% response at 10 hours**

p<0.0001 for all timepoints

CLARITY 2, day 1 results, full analysis set. Near visual acuity was assessed at 40cm using Monocular BCDVA (best-corrected distance visual acuity)

LENZ

Nearly all participants (95%) achieved a ≥2-Line improvement



95% of participants achieved ≥2-Line improvement **at 1 hr**

69% of participants achieved ≥2-Line improvement **at 10 hrs**

≥2-Line improvement seen as **clinically meaningful**

p<0.0001 for all timepoints

CLARITY 2, day 1 results, full analysis set. Near visual acuity was assessed at 40cm using Monocular BCDVA (best-corrected distance visual acuity)

LENZ

Positive impact to distance vision in normal light



Statistically significant **improvement of 2 - 4 letters** of distance vision in **normal light** at all time points **p<0.0001**

No negative impact to distance vision in **low light**

CLARITY 2, day 1 results, full analysis set, n=77 for LNZ100 and n=76 for LNZ101. Distance visual acuity was assessed at 4m and 0.5h, 1h, 3h, 5h, 7h, 8h, 9h and 10h for normal light, and 1h, 3h and 10h for low light conditions. Monocular BCDVA (best-corrected distance visual acuity).

LENZ

Consistent near vision improvement over 28 days



Reproducible and robust near vision improvement across study days

Consistent and well-controlled with a **low placebo response rate**

p<0.0001 for all timepoints vs vehicle

CLARITY 2, Based on full analysis set. Near visual acuity was assessed at 40cm. Monocular BCDVA (best-corrected distance visual acuity); LNZ100 day 1 and day 15 n=77, day 28 n=76, Vehicle day 1 n=76, day 15 and day 28 n=75

LENZ

Well tolerated with vast majority of AEs reported as mild

Pooled analysis of CLARITY 1 & 2

	LNZ100 N=234 n(%)		**Vehicle** N=76 n(%)
Ocular AEs			
Instillation site irritation *(mild stinging upon instillation)*[1]	47 (20.1%)	100% mild	8 (10.5%)
Visual impairment *(mild dimness)*[1]	31 (13.2%)	100% mild	1 (1.3%)
Hyperemia *(mild eye redness)*	21 (9.0%)	100% mild	2 (2.6%)
Non-Ocular AEs			
Headache	27 (11.5%)	89% mild 7% moderate	3 (3.9%)

No serious treatment related adverse events

Ocular AEs classified by participants and investigators as **100% mild**

Placebo corrected **headache incidence of 7.6%** and mostly reported as **mild**

All AEs expected to be transient in line with Phase 2 observations

List contains all AEs over 5%, [1] general most common descriptor used by participants

Patient satisfaction confirms commercial opportunity for the vast majority of 128M US presbyopes

90%

Noticed improvement in near vision

75%

Would continue to use after study

81%

Would use 4-7 days/week[1]

Pooled responses of LNZ100 in Clarity 1 & 2 on day 28, n=223. Based on patient questionnaire “Reflecting on the last 30 days…” “Have you noticed an improvement in your near vision/ability to see up close after taking the drop?”, “Would you be interested in continuing to use these eye drops after the study?”, “How many days a week are you likely to use these eye drops?” 1. % of participants that indicated ‘yes’ to “Would you be interested in continuing to use these eye drops after the study?”

Across all CLARITY trials 378 participants for a combined 30,000+ days on LNZ100 without treatment related serious AEs

Ages 45 – 75, Mean 55 years[1]	Refractive range -4D SE to +1D SE	Inclusive of post-LASIK presbyopes and pseudophakes	Baseline near visual acuity 20/50 or worse[1]



1. CLARITY 1 & 2 25 sites participated in CLARITY 1, 17 sites participated in CLARITY 2 and 40 sites participated in CLARITY 3

LNZ100 consistent performance across CLARITY 1 & 2; LNZ101 showed similar but not superior efficacy

Participants (%) with ≥ 3-line and ≥ 2-line improvement in BCDVA at near and no loss of ≥ 5 letters at 4m, at all time points p<0.0001 vs. control

		CLARITY 1			CLARITY 2		
		LNZ100	LNZ101	Brimonidine	LNZ100	LNZ101	Vehicle
30 Min (Onset)	3 line	72%	56%	14%	71%	63%	12%
	2 line	87%	78%	38%	91%	72%	22%
3 Hour (Primary for ≥ 3-line)	3 line	64%	49%	12%	71%	57%	8%
	2 line	83%	70%	29%	91%	81%	24%
10 Hour (Duration)	3 line	27%	37%	6%	40%	39%	5%
	2 line	61%	59%	21%	69%	67%	21%

LNZ100 selected as lead candidate targeting NDA Submission mid-2024

Day 1 Based on full analysis set. Near visual acuity was assessed at 40cm. Monocular BCDVA (best-corrected distance visual acuity)

Additional CLARITY data to be provided at upcoming industry conferences

LENZ THERAPEUTICS

Visit: LENZ-tx.com for more information